AzTrials
AzTrials

Early Prediction for Sepsis Induced Acute Lung InjuryNCT04541264

Radiomics Markers to Predict Sepsis Induced Acute Respiratory Distress Syndrome

An observational study of Early Prediction for Sepsis Induced Acute Lung Injury, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Introduction: Sepsis-induced acute respiratory distress syndrome(SI-ARDS) is a common complication of severe sepsis and is an independent contributor to poor prognosis of patients. Read more about this study

Who is it for?
Ages 18 to 90 years
What is being tested?
radiomic of chest CT
How many people
300 participants
Where
1 siteChina
Study dates
1 Jun 2021to 31 Dec 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: We plan to recruit 160 patients in discovering group, 40 patients in internal validation, and 100 patients in external validation group. Patients between 18 and 80 years of age with sepsis and septic shock will be screened for eligibility

Who may be able to join

  • Clinical diagnosis of sepsis
  • Clinical diagnosis of ARDS
  • Written informed consent in external validation cohort

Who cannot join

  • admission stay <24hours,
  • the presence of end-stage lung disease or long-term oxygen therapy,
  • critically ill patients who have started mechanical ventilation caused by SA-ARDS before admission,
  • a history of lung transplantation and chronic obstructive pulmonary disease,
  • cancer patients not/have received chemotherapy

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510000

    Li Li, 02034071029, lil3@mail.sysu.edu.cn

    Recruiting

Other trials in China

About this study

Official title: Application of Radiomics as Predicted Marker for Patients With Sepsis Induced Acute Respiratory Distress Syndrome:a Protocol for an Observational Ambispective Cohort Study

Introduction:

Sepsis-induced acute respiratory distress syndrome(SI-ARDS) is a common complication of severe sepsis and is an independent contributor to poor prognosis of patients. It remains a clinical challenge to identify the SI-ARDS early and accurately, which could optimize the treatment strategy and reduce the mortality risk. Radiomics high-dimensional features extracted from CT images offer an insight into microvascular damage of SI-ARDS that are imperceptible to human eyes and aspects of intra-alveolar heterogeneity with potential prognostic relevance.

Read more

Methods:

Study design Investigators screened all patients with sepsis and septic shock who are treated in Sun Yat-sen Memorial Hospital, Sun Yat-sen University during the period from 1 May 2015 and 30 May 2022. Patients were recruited retrospectively from May 2015 to April 2021 as discovering group, and prospectively during the period from May 2021 to May 2022 as validation group. Follow-up will conducted until April 2023.

Cohort descriptions and definitions Investigators plan to recruit 160 patients in discovering group, 40 patients in internal validation group, and 100 patients in external validation group. Patients between 18 and 80 years of age with sepsis and septic shock will be screened for eligibility. SI-ARDS is defined by sequential occurrence of the sepsis-3 consensus criteria for sepsis and the Berlin Definition for ARDS. The exclusion criteria are:

  1. admission stay <24hours,
  2. the presence of end-stage lung disease or long-term oxygen therapy,
  3. critically ill patients who have started mechanical ventilation caused by SI-ARDS before admission,
  4. a history of lung transplantation and chronic obstructive pulmonary disease,
  5. cancer patients not/have received chemotherapy.

Outcome measures In this study, the primary outcome measure was the occurrence rates of acute respiratory distress syndrome(ARDS). It refers to the occurrence of sepsis patients progressed into ARDS.

Secondary outcome measures were as follows:

1.28-day mortality 2.ventilator-free days 3.respiratory failure-free days

Data collection All clinical data were collected by investigators and trained personnel. Each participant's data will be filled in electronic case report forms (CRF) and store online using REDCap (Research Electronic Data Capture).

Discussion:

SI-ARDS is one common severe complication with critically ill sepsis patients, which causes high mortality and poor prognosis. Early ARDS patient(arterial oxygen tension/inspired oxygen fraction [PaO2/FIO2] ≤ 300 mmHg but > 200 mmHg) may not require invasive mechanical ventilation, and is more readily reversible than acute respiratory distress syndrome(ARDS). In this ambispecive cohort study, investigators developed and validated novel nomograms incorporating the radiomics signature and clinical signature to provide an easy-to-use and individualized prediction of SI-ARDS occurrence and severe degree in patients with early stage.

Being tested
radiomic of chest CT
Keywords
radiomics, sepsis, acute respiratory distress syndrome, deep learning, prediction model
Medical subject headings
Sepsis, Respiratory Distress Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • radiomic of chest CTDiagnostic test

    radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.

Study groups in NCT04541264
Study groupRoleWhat they receive
Model reconstruction cohort160 patients were recruited retrospectively from May 2015 to April 2020 as discovering group.
Receives: Diagnostic Test: radiomic of chest CT
Internal validation cohort40 patients were recruited retrospectively from May 2015 to April 2020 as internal validation group.
Receives: Diagnostic Test: radiomic of chest CT
External validation cohort100 patients will be recruited prospectively during the period from May 2020 to April 2021 as external validation group.
Receives: Diagnostic Test: radiomic of chest CT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. occurrence rates of acute respiratory distress syndrome(ARDS)

    It refers to the occurrence of sepsis patients progressed into ARDS in all patients enrolled into the study

    Measured: from date of admission until the date of disease progressing to ARDS, assessed up to 28days

Secondary outcomes (3)
  1. 28-day mortality

    a cox proportion hazards regression model was used to analysis the survival outcome of patients with sepsis within 28 days according to radiomics characteristics

    Measured: from date of admission until the date of death from any cause, assessed up to 28days

  2. ventilator-free days

    defined as the number of calendar days after initiating ventilator unassisted breathing to day 28 after admission

    Measured: from date of admission until the date of ventilation or discharge from hospital, assessed up to 28days

  3. respiratory failure-free days

    defined as the day without evidence of non-respiratory organ failure

    Measured: from date of admission until the initiating date of respiratory failure, assessed up to 28days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Sep 2020
  2. Study start1 Jun 2021
  3. Primary completion17 Aug 2023 (estimated)
  4. Study completion31 Dec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
300 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04541264
Sponsor's protocol ID
SYSEC-KY-KS-2020-122
Status last verified
Jun 2021
First submitted
27 Aug 2020
Last updated
18 Jun 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Individual participant data in this research can contact lil3@mail.sysu.edu.cn for reasonable requests.

Questions about this trial

What is this clinical trial studying?

An observational study of Early Prediction for Sepsis Induced Acute Lung Injury, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact LI LI (02034071029, lil3@mail.sysu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

occurrence rates of acute respiratory distress syndrome(ARDS) (time frame: from date of admission until the date of disease progressing to ARDS, assessed up to 28days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in